

# Atherosclerosis as an autoinflammatory disease

Dorian O. Haskard

Vascular Sciences Section  
National Heart and Lung Institute



Imperial College  
London


# **Atherosclerosis – plan of talk/learning objectives**

- Cellular pathology of atherosclerosis
- Link between cholesterol and inflammation
- Investigating molecular mechanisms
- Roles of humoral and cellular immunity

# World disease burden

1990

2020





*Adapted from Lopez and Murray (1998) Nature Med 4: 1241*




# Type II lesion


## Type IV lesion



**Debris (eg modified lipoproteins, apoptotic cells)**




**Reversible fatty lesions**




**Irreversible remodelling**

*wound healing*  
**Stable plaques**




*inflammation/thrombosis*  
**Unstable plaques**



Ischaemia


**Angina**  
**Intermittant claudication**



Thrombosis and infarction

**Acute coronary syndromes**  
**Stroke**  
**Peripheral gangrene**

# Relative importance of risk factors




*Danesh et al 2004 N Engl J Med 350:1387*



# History – the cholesterol hypothesis





N. N. Anitschkow  
Military Medical Academy of St Petersburg  
(circa 1904)





Plaque from a rabbit fed  
cholesterol for 106 days and  
then chow for >2 years



Low density lipoproteins (LDL) deposit in the subintimal space at sites of low/complex flow, and bind to matrix proteoglycans




From: Tabas, I. et al. *Circulation* 2007;116:1832-1844




# LDL modification in the arterial wall happens before macrophage infiltration

MDA-lysine  
(oxidised LDL)



monocyte/mø



# Macrophage scavenger receptors




from Pluddemann et al (2007) Methods 43:207





# Foam cells




*from Dr Howard K*



# Foam cells




Faggiotto et al 1984 Arteriosclerosis 4:323





# Homeostatic debris disposal

monocyte adhesion to endothelium




adhesion molecules

cytokines


chemokines

oxidised phospholipids

monocyte  
recruitment




modified LDL




activated  
macrophages  
(foam cells)

DISPOSAL  
(via blood or  
lymph)



# Inflammatory basis of atherosclerosis


monocyte adhesion to endothelium




adhesion molecules (eg VCAM-1)

cytokines  
chemokines  
ox-phospholipids


monocyte  
recruitment



modified LDL



activated  
macrophages  
(foam cells)




free radicals

proteases

VSMC growth  
factors

angiogenic  
factors



apoptosis





# Main cellular players

- **Vascular endothelial cells**
  - Barrier function (eg to lipoproteins)
  - Leukocyte recruitment
- **Platelets**
  - Thrombus generation
  - Cytokine and growth factor release
- **Monocyte-macrophages**
  - Foam cell formation
  - Cytokine and growth factor release
  - Major source of free radicals
  - Metalloproteinases
- **Vascular smooth muscle cells**
  - Migration and proliferation
  - Collagen synthesis
  - Remodelling and fibrous cap formation
- **T lymphocytes**
  - Macrophage activation

# Step-wise progression of atherosclerotic plaques



# Vasa vasorum are the back-door for leukocyte recruitment





*De Boer et al (1999) Cardiovasc Res 41:443.*






# Mouse models of atherosclerosis

- **ApoE<sup>-/-</sup>**
  - 34kd component of VLDL and chylomicrons
  - ligand for LDL receptor
- **LDL receptor <sup>-/-</sup>**
  - Mutations in familial hypercholesterolaemia






# Atherosclerosis in *Ldlr*<sup>-/-</sup> mice




wild-type



*Ldlr*<sup>-/-</sup> high fat 13 mo

*Ishibashi et al 1994 JCI 93:1885*



# Influence of adhesion molecules, chemokines and cytokines on mouse atherosclerosis

## Accelerators

### Adhesion molecules

P-selectin  
E-selectin  
ICAM-1  
VCAM-1

### Chemokines & receptors

MCP-1  
CCR2  
CXCR2  
CX3CR1


### Cytokines

IL-1  
TNF $\alpha$   
IL-4  
IL-6  
IL-12  
IL-18  
IFN $\gamma$


## Decelerators

IL1RA  
TGFb  
IL-10


**Debris (eg modified lipoproteins, apoptotic cells)**




**Reversible fatty lesions**



**Irreversible remodelling**




*wound healing*




**Stable plaques**

environmental  
and genetic  
influences




*inflammation*



**Unstable plaques**

# Role of complement in atherosclerosis

Apoptotic cells  
Cholesterol crystals  
Denatured LDL  
Microparticles  
Immune-complexes  
Endotoxin




Immunohistological evidence for complement activation in human atherosclerosis

C6 deficient rabbits on a high fat diet are protected (*Geertinger & Sørensen 1977; Schmiedt et al 1998*)





C3<sup>-/-</sup> mice show impaired progression to complex lesions (*Buono et al, 2002*)

# C1q deletion accelerates atherosclerosis on a low fat diet (*Bhatia et al 2007 Am J Pathol*)






# *C1qa*<sup>-/-</sup>*Ldlr*<sup>-/-</sup> mice show impaired apoptotic cell clearance



*cleaved caspase 3*

Bhatia et al (2007) Am J Pathol 170:416

C1q deletion accelerates atherosclerosis on a low fat diet  
(*Bhatia et al 2007 Am J Pathol*)



Accelerated atherosclerosis in mice with MBL-A and MBL-C deficient bone marrow  
(*Matthijsen et al 2009 Circulation*)

Acceleration of lesions in mice with DAF or CD59 deficiency (*Yun et al 2008 ATVB, Leung et al 2009 Am J Pathol*)

# Induction of DAF and CD59 in endothelial cells

**DAF is induced by  $\text{TNF}\alpha$ ,  $\text{IFN}\gamma$ , thrombin, VEGF, bFGF, C5b-9 and statins**

*Mason et al (1999) Blood 94:1673*

*Lidington et al (2000) Blood 96:2784*


*Mason et al (2001) Arthritis Rheum 44:138*

*Mason et al (2002) Circulation Research 91:696*

*Mason et al (2002) Am J Physiol 282:C578*

*Ahmad et al (2003) Immunology 110:258*

*Mason et al (2004) J Biol Chem 279:41611*




**CD59 is upregulated by hypoxia and shear-stress**

*Kinderlerer et al (2006) Arthritis Res Therapy 8:R130*

*Kinderlerer et al (2008) J Biol Chem 283:14636*

# Role of complement in atherosclerosis

Apoptotic cells  
Cholesterol crystals  
Denatured LDL  
Microparticles  
Immune-complexes  
Endotoxin



What is the role of IgM natural antibodies in the system?



# Natural IgM antibodies

- germline encoded
- secreted largely by B1 cells
- scavenger functions (bacteria, oxLDL, apoptotic cells)
- Bind ubiquitous epitopes (eg phosphorylcholine)
- immunization studies suggest atheroprotective effects
- can be explored directly using secretory IgM<sup>-/-</sup> mice, generated by mutation of the C<sub>μ</sub> gene


Green –CD68 (møs)

Red –IgM

Blue –nuclei




# IgM and C1q are required for uptake of apoptotic cells *in vitro*







# IgM deficiency accelerates atherosclerosis




## Low fat



## High fat





# Hypothetical model of the role of complement and IgM natural antibodies in atherosclerosis




**Homeostatic clearance**

# Alternative pathway




**Hypothesis** Activation of the alternative pathway stimulates proinflammatory downstream complement activation by over-riding complement inhibitors and is pro-atherogenic

# Factor B deficiency protects *Ldlr*<sup>-/-</sup> mice from atherosclerosis accelerated by endotoxin



# Reduced local complement activation in endotoxin-treated Factor B deficient *Ldlr*<sup>-/-</sup> mice





# Complement, antibodies and the homeostatic balance in atherosclerosis

- Natural IgM antibodies and upstream complement activity (classical and lectin pathways) are homeostatic, probably through enhancing debris clearance.
- Activation of downstream pro-inflammatory effects are prevented under homeostatic conditions by complement regulators (eg DAF, CD59).
- Over-activation of the system via the alternative pathway overrides this regulation and is proatherogenic.

# Role of T lymphocytes in atherosclerosis

- Atherosclerotic plaques contain MHC Class II positive dendritic cells and T lymphocytes at all stages
- Plaque T cells show evidence of activation (eg HLA-DR, IFN $\gamma$ )
- Plaque T cells are oligoclonal and ~10% react with oxidised LDL
- T cells may activate macrophages and VSMC (eg via CD40L-CD40 contact interactions)
- Activated T cells are present in the circulation during acute coronary syndromes (ie plaque instability)

# Effects of CD4 T cell transfer



*Zhou et al (2006) ATVB 26:864*



# Summary

- Atherosclerosis can be viewed as a dynamic chronic inflammatory disease of arteries
- The innate immune system (macrophages, complement, natural IgM antibodies) regulate the safe disposal of lipoproteins and other debris from the arterial wall and is intrinsically protective
- Overdrive of the innate immune system leads to irreversible remodelling, and this may be accelerated by adaptive T cell-dependent immune mechanisms